Home » Topics » Analysis and data insight

Analysis and data insight
RSS

Dec. 9-13, 2019 week in review: Biopharmas impress investors at ASH

December 13, 2019

A quick look back at top stories.

Phase I clinical trials: November 2019

December 13, 2019

Therapeutic area data reported by biopharma companies on phase I trials in November 2019.

Phase II clinical trials: November 2019

December 13, 2019

Therapeutic area data reported by biopharma companies on phase II trials in October 2019.

Phase III clinical trials: November 2019

December 13, 2019

Therapeutic area data reported by biopharma companies on phase III trials in November 2019.

Biggest gainers and losers for the week of Dec. 9-13, 2019

December 13, 2019

The top 10 biopharma stock gainers and losers for the week.

Money raised by biopharma: 2019 vs. 2018

December 13, 2019

Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018.

Biopharma money raised: Jan. 1-Dec. 12, 2019

December 13, 2019

Year-to-date money raised in public, private and other financings of biopharma companies.

Market movers

Biopharmas impress investors with clinical progress at ASH

December 11, 2019

By Peter Winter

The American Society of Hematology meeting closed yesterday and served to shine the light on the latest research and progress of new therapies targeting hematological malignancies as well as other serious blood disorders. Specifically, a great deal of attention was focused on the treatment of blood cancers and, judging by the increase in value of the BioWorld Cancer index, investors and analysts alike were impressed with what they heard.

stock market

Impact of trial failure

Neurological Diseases index dips following strong performance

December 10, 2019

By Peter Winter

After dropping to its lowest valuation at the end of September, the BioWorld Neurological Diseases index, a price-weighted index of public biopharmaceutical companies that are focused on developing therapies to treat neurological diseases, got on a roll and climbed 22% during the next two months. However, a surprising trial failure reported by Sage Therapeutics Inc. last week served to eat into those index gains.

Gainers-and-losers

Biggest gainers and losers for the week of Dec. 2-6, 2019

December 6, 2019

The top 10 biopharma stock gainers and losers for the week.

Popular Stories

Bioworld MedTech’s Oncology Extra
BioWorld MedTech
Keeping you up to date on recent developments in oncology.
FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system
BioWorld MedTech
The U.S. FDA has cleared Cochlear Ltd.’s newest cochlear implant, the Osia 2 system, an active implantable bone conduction hearing system. Unlike Cochlear’s...
Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity
BioWorld
LONDON – It’s no secret that American citizens pay the most for drugs, but the extent of the disparity is laid bare in a new index of the prices of 13 medicines...
Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms
BioWorld
Commissioner of the FDA for five years starting in 1984, Frank Young relished his position “at the vortex of controversy” as he sought to deal with the AIDS...
Biopharma companies continue their strong momentum in November
BioWorld
After being in the doldrums for the majority of the year, public biopharmaceutical companies, it appears, have turned the corner and are now on a major upswing.

cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.